Infinity Pharmaceuticals, Inc. Presents the Chemistry and Discovery of IPI-926, Its Novel Hedgehog Signaling Pathway Inhibitor, At American Chemical Society Meeting

CAMBRIDGE, Mass. and SALT LAKE CITY, March 25, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced data on the chemistry leading to the discovery of its novel Hedgehog signaling pathway inhibitor, IPI-926. These data are being highlighted in three posters and one invited oral presentation at the 237th American Chemical Society (ACS) National Meeting & Exposition, being held in Salt Lake City, Utah from March 22 through March 26, 2009.